SCHEDULE: D.E. Shaw Entities Adjust Gossamer Bio Stake

D.E. Shaw entities report transactions in Gossamer Bio common stock over the past 60 days, with significant net sales.

Summary

• This filing is an amendment to a Schedule 13D, reporting transactions in Gossamer Bio, Inc. common stock by D.E. Shaw entities.
• The reporting persons include Valence Portfolios, L.L.C., D.E. Shaw & Co., L.L.C., D.E. Shaw & Co., L.P., and David E. Shaw.
• As of June 5, 2026, there were 488,846,722 Gossamer Bio common shares outstanding.
• Valence Portfolios, L.L.C. beneficially owns 38,362,468 shares (7.8% of outstanding).
• D.E. Shaw & Co., L.L.C. beneficially owns 40,242,495 shares (8.2% of outstanding).
• D.E. Shaw & Co., L.P. beneficially owns 40,630,726 shares (8.3% of outstanding).
• David E. Shaw may be deemed to beneficially own 40,630,726 shares (8.3% of outstanding) due to his positions in related entities.
• Schedule I details transactions in the securities of Gossamer Bio, Inc. during the past sixty days, primarily involving sales by Valence and Cogence (an affiliate not explicitly listed as a reporting person in the cover page but mentioned in the text).
• The transactions occurred between June 12, 2026, and July 1, 2026.
• The prices per common share ranged from approximately $0.16 to $0.18.
• The filing also references a Transaction Support Agreement with the Issuer dated May 18, 2026, and a Form of Voting Agreement dated May 18, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the significant net sales of stock by the reporting entities, suggesting a reduction in their investment or confidence.

Negatives

• The reporting persons, through various entities, have engaged in significant net sales of Gossamer Bio common stock over the past 60 days.
• Valence Portfolios, L.L.C. sold a total of 4,199,911 shares.
• Cogence sold a total of 285,000 shares.
• The aggregate number of shares sold by Valence and Cogence during the period is substantial, indicating a reduction in their holdings.

Future Outlook

This filing primarily reports past transactions and beneficial ownership. It does not contain specific forward-looking statements or guidance from Gossamer Bio, Inc. itself, but rather details the trading activities and ownership stakes of D.E. Shaw entities.

Industry Context

StockSavvy.ai notes that Schedule 13D filings are crucial for tracking significant changes in beneficial ownership of public companies. The substantial net sales reported by D.E. Shaw entities could indicate a shift in their investment strategy or a response to company-specific developments, which investors should monitor closely.

Stakeholder Impact

• Shareholders: The significant net sales by D.E. Shaw entities could put downward pressure on the stock price and may signal a lack of confidence from a major investor.
• Management of Gossamer Bio, Inc.: The actions of D.E. Shaw entities, as significant shareholders, may influence discussions regarding company strategy and governance.
• Creditors: While not directly impacted by stock transactions, any significant shift in major shareholder sentiment could indirectly affect perceptions of company stability.

Next Steps

• The reporting persons will continue to monitor the business and affairs of the Issuer.
• The reporting persons may, from time to time, purchase additional securities of the Issuer, sell securities of the Issuer, or retain their present holdings.
• The reporting persons may engage in discussions with management of the Issuer, the Issuer's board of directors, other security holders of the Issuer, and other relevant parties concerning the Issuer's business, management, and future strategies.

Key Dates

Recommendation

The filing primarily details past stock transactions and ownership stakes by D.E. Shaw entities, showing significant net sales. While this indicates a reduction in their holdings, it does not provide new operational or financial data for Gossamer Bio, Inc. itself. Therefore, a 'hold' recommendation is appropriate, suggesting investors await further company-specific news or performance updates before making a decisive move.

Keywords

Gossamer Bio, Schedule 13D, D.E. Shaw, Valence Portfolios, Cogence, Securities Trading, Beneficial Ownership, Stock Transactions, SEC Filing